Skip to main content
OpenTrials
Completed

NCT Number: NCT00593034

Medical Office Intervention for Adolescent Drug Use - Attention Study Supplement

This study will use the CCPT II to assess attention in 12-21 year olds enrolled in a randomized controlled trial of a brief behavioral treatment for substance abuse.

This study will describe at baseline levels of attention using a well validated instrument (Connors Continuous Performance Test II) and explore the association between attention levels and substance use. The primary study hypothesis is that lower initial levels of substance use (as measured by percent days abstinent) will be associated with higher attention levels. We envision that this data will inform a better understanding of how attention may modify treatment response.

Completed

Looking for future studies?

Notify Me

Key information

Age range

12 year–21 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Children's Hospital Boston

Boston, Massachusetts, 02115, United States

About this study

Research among adolescents with substance use problems presents unique challenges to investigators. Issues with recruitment, confidentiality, and follow-up have been cited as common limitations to research in this area. One likely contributor to decreased treatment persistence and follow-up is the limited ability to sustain attention that many adolescents, especially those with substance problems, may manifest. (Taper, 2002) Thus, assessing attention before beginning substance abuse treatment has the potential not only to inform the science of adolescent addiction medicine, but also to guide the development of therapies to specifically address attention deficits among adolescent substance users. Adolescent outpatients being treated for substance problems have not been systematically studied for clinical or subclinical attention levels.

The primary aims this study are as follows:

  • To test the feasibility of administering the Connors Continuous Performance Test II (CCPT II), a well validated measure of attention, to a sample of 12-21 year old patients receiving treatment for substance abuse.
  • To obtain baseline descriptive statistics on the CCPT II in a previously understudied group of young patients receiving treatment for substance abuse.
  • To estimate the magnitude of the association between substance use and levels of attention at baseline before treatment.
  • To explore the degree to which attention may affect response to substance abuse treatment in general and specifically motivational interviewing.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • CRAFFT score of 1 or more
  • Have used cannabis, alcohol or another drug on at least two occasions during the 30 days preceding their visit
  • Can read and understand English

Exclusion criteria

  • Require immediate hospitalization or referral to residential substance abuse treatment
  • Will not be available to complete the study assessments over the next 9 months.

Treatment and study plan

Primary outcomes

  1. Score on the Connors Continuous Performance Test II (CCPT II)

    Time frame: Baseline

Secondary outcomes

  1. Percentage of days abstinent

    Time frame: 6 months

Sponsors and collaborators

Lead sponsor

Boston Children's Hospital

Other

Registry information

Official study title

Medical Office Intervention for Adolescent Drug Use - Research Supplement for Under-represented Minorities

Important dates

Study start
2007
Primary completion
2008
Study completion
2008
First posted
Jan 14, 2008
Registry last updated
Mar 8, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.